Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol's Focused BioPharma Strategy Starts To Pay Off

Executive Summary

While many of the world's leading drug companies have relied on mega-mergers and diversified portfolios to drive growth over the last five years, Bristol-Myers Squibb Co. has taken a different tact, jettisoning non-core businesses, slashing overhead and jobs, and announcing a plan to focus its portfolio solely on biopharma.

You may also be interested in...

BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier

TOKYO - Bristol-Myers Squibb Co. expects to stop a five-year skid in Japan sales by the end of FY2011, and CEO Lamberto Andreotti said the company will utilize its large cash reserves for new business development opportunities in an effort to become a top 20 company in Japan

BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier

Ranked 14th in pharma sales globally, the company isn't even among the top 20 pharmacos in Japan--but it plans on a change in portfolio mix and an emphasis on business development activities to change that profile.

BMS Adds To String Of Pearls: $470 Mil. Deal With French Biotech Brings Innate Immunity Approach Into Its R&D Pipeline

BMS deal with Innate Pharma strengthens the U.S. company's focus on cancer immunotherapy, and adds fillip to biotech companies in France.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts